DP8
CervoMed Inc., a a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of th… Read more
DP8 (DP8) - Total Liabilities
Latest total liabilities as of September 2025: €4.60 Million EUR
Based on the latest financial reports, DP8 (DP8) has total liabilities worth €4.60 Million EUR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
DP8 - Total Liabilities Trend (2021–2024)
This chart illustrates how DP8's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
DP8 Competitors by Total Liabilities
The table below lists competitors of DP8 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Blue Gold Limited Class A Ordinary Shares
NASDAQ:BGL
|
USA | $2.70 Million |
|
Best Agrolife Limited
NSE:BESTAGRO
|
India | ₹11.54 Billion |
|
Blueone Card Inc
PINK:BCRD
|
USA | $2.30 Million |
|
Beammwave AB B
ST:BEAMMW-B
|
Sweden | Skr6.25 Million |
|
Chia Ta World Co Ltd
TW:2033
|
Taiwan | NT$171.71 Million |
|
Carclo plc
PINK:CCEGF
|
USA | $103.43 Million |
|
COWELL FASHION Co.Ltd
KQ:033290
|
Korea | ₩576.69 Billion |
Liability Composition Analysis (2021–2024)
This chart breaks down DP8's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.66 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how DP8's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for DP8 (2021–2024)
The table below shows the annual total liabilities of DP8 from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €3.88 Million | +49.45% |
| 2023-12-31 | €2.60 Million | -93.07% |
| 2022-12-31 | €37.44 Million | +1178.92% |
| 2021-12-31 | €2.93 Million | -- |